Open-to-Accrual Therapeutic Trials


Thoracic Oncology (Lung)

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

CC-16053  ClinicalTrials.gov:   NCT03257722

A Phase Ib /II Trial of Pembrolizumab and Idelalisib in Patients with Non-Small Cell Lung Cancer (NSCLC) Z. Hao Lisa Marshall & Kelly Jenkins Non-Small Cell Lung Cancer (NSCLC) Ib/II

M14-361  ClinicalTrials.gov:   NCT02289690

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naive Extensive Stage Disease Small Cell Lung Cancer Z. Hao Kelly Jenkins Small Cell Lung Cancer I/II

A081105 (ALCHEMIST)  ClinicalTrials.gov:   NCT02193282

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) S. Ghamande Inquiries Small Cell Lung Cancer III

E4512 (ALCHEMIST)  ClinicalTrials,gov:   NCT02201992

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein S. Ghamande Inquiries Small Cell Lung Cancer III

EA5142  ClinicalTrials.gov:   NCT02595944

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancer S. Ghamande Inquiries Small Cell Lung Cancer III

S0819  ClinicalTrials.gov:   NCT00946712

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) S. Ghamande Inquiries  Small Cell Lung Cancer III